EVMN — Evommune Cashflow Statement
0.000.00%
Last trade - 00:00- $520.64m
- $415.98m
- $7.00m
Annual cashflow statement for Evommune, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -34.1 | -66.8 |
| Depreciation | ||
| Non-Cash Items | -0.261 | -0.098 |
| Other Non-Cash Items | ||
| Changes in Working Capital | 3.34 | 7.42 |
| Change in Prepaid Expenses | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Change in Other Liabilities | ||
| Cash from Operating Activities | -30 | -58.2 |
| Capital Expenditures | -0.118 | -0.088 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | -48.3 | -3.9 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | -48.4 | -3.99 |
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 63.8 | 49.4 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | -14.7 | -12.8 |